Uysal, AyseErkurt, Mehmet AliKuru, IrfanKaya, EminBerber, IlhamiSarici, AhmetBicim, Soykan2024-08-042024-08-0420231309-9469https://doi.org/10.5472/marumj.1244684https://hdl.handle.net/11616/101454Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ mu L in the peripheral blood (PB) on the 4th day of mobilization.Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined.Results: The median CD34+ cell count in PB on the 4th day was 5.2/mu L (0.1-13.4), which was determined to increase 206.6-fold (31.5749347) to 924.80 /mu L (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= - 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106).Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.eninfo:eu-repo/semantics/openAccessApheresisStem cellMobilizationPlerixaforPreemptiveArticle361657110.5472/marumj.12446842-s2.0-85164248915Q4WOS:000926968200011Q4